Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival

Raze, Thomas; Lacour, Brigitte; Cowppli-Bony, Anne; Delafosse, Patricia; Velten, Michel; Trétarre, Brigitte; Défossez, Gautier; Hammas, Karima; Woronoff, Anne‐Sophie; Ganry, O.; Plouvier, Sandrine; Coureau, Gaëlle; Guizard, Anne‐Valérie; Bara, Simona; Monnereau, Alain; Daubisse‐Marliac, Laetitia; Troussard, Xavier; d’Almeida, Tania; Baldi, Isabelle; Bouvier, Anne–Marie; Boissel, Nicolas; Clavel, Jacqueline; Désandes, Emmanuel

doi:10.1089/jayao.2020.0017

Cited by 25 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcomas are rare malignancies, accounting for <1% of all adult cancers and approximately 10% of all malignant solid tumors in adolescents and young adults 1 . The term sarcoma represents more than 100 different histologic entities, best described in the 2020 World Health Organization (WHO) standard classification of tumors of soft tissue and bone 2 .…”

Section: Introductionmentioning

confidence: 99%

Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM)

Amadéo

Penel

Coindre

et al. 2022

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND: Sarcomas are rare, heterogeneous, ubiquitously localized malignancies with many histologic subtypes and genomic patterns. The survival of patients with sarcoma has rarely been described based on this heterogeneity; therefore, the authors' objective was to estimate survival outcomes in patients who had sarcomas using the 2020 version of the World Health Organization classification of soft tissue and bone tumors. METHODS: Patients older than 15 years who had incident sarcoma diagnosed between 2005 and 2010 were extracted from 14 French population-based cancer registries covering 18% of the French metropolitan population. Vital status for each patient was actively followed up to June 30, 2013. Net survival (NS) was estimated using the unbiased Pohar-Perme method. RESULTS: Overall, 4202 patients were included. NS declined with increasing age at diagnosis. According to topographic groups, large 5-year NS disparities were observed, ranging from 47% among women with gynecologic sarcomas to 89% among patients with skin sarcomas. Patients with soft tissue, bone, and gastrointestinal sarcomas had 5-year NS rates of 53%, 61%, and 70%, respectively. Similar heterogeneity was observed according to histologic subtypes, with 5-year NS ranging from 19% for patients with angiosarcomas to 96% for patients with dermatofibrosarcomas. Patients with sarcoma who displayed missense mutations had a better 5-year NS (74%); those with MDM2-amplified sarcomas had the worst NS (45%). CONCLUSIONS: NS rates in patients with sarcoma are presented here for the first time based on the 2020 World Health Organization classification applied to population-based registry data. Large prognostic heterogeneity was observed based on age, topographic and histologic groups, and genomic alteration profiles, constituting a benchmark for future studies and clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM)

Amadéo

Penel

Coindre

et al. 2022

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Different tumors in AYAs were investigated between 2000 and 2016 in France. For AYA patients with ES and OSA, the 5-year OS was around 60% and lower (18). White et al underlined that AYA patients with rare sarcomas, including ES and OSA should be treated in reference centers (19).…”

Section: Discussionmentioning

confidence: 99%

Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management

Minichsdorfer

Steinbrecher

Kölz

et al. 2021

In Vivo

View full text Add to dashboard Cite

“…Studies in Europe [ 18 , 20 , 22 , 42 , 46 , 47 , 48 , 49 , 50 ] and North America [ 23 , 43 , 45 ], evaluating AYAs included in pediatric protocols show 5-year OS higher than 90%, with no differences compared to children. On the other hand, EFS was lower in adolescents aged >13 years than in younger patients included in the POG 8725 protocol [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Hodgkin’s Lymphoma in Children and Adolescents. A Twenty Year Experience with MH’96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols

Burnelli

Fiumana

Rondelli

et al. 2020

Cancers

View full text Add to dashboard Cite

Adolescents and young adults (AYAs) represent a distinct group of patients. The objectives of this study were: To compare adolescent prognosis to that of younger children; to compare the results achieved with the two consecutive protocols in both age groups; to analyze clinical characteristics of children and adolescents. Between 1996 and 2017, 1759 patients aged <18 years were evaluable for the study. Five hundred and sixty patients were treated with the MH’96 protocol and 1199 with the LH2004 protocol. Four hundred and eighty-two were adolescents aged ≥15 years. Patients in both age groups showed very favorable prognoses. In particular, OS improved with the LH2004 protocol, especially in the adolescent group and in the low risk group, where radiation therapy was spared. Adolescent characteristics differed significantly from the children’s according to sex, histology, and the presence of symptoms. Remarkable is the decrease both in mixed cellularity in the children and in low stages in both age groups in the LH2004 protocol with respect to MH’96 protocol. Based on our experience, adopting pediatric protocols for AYA does not compromise patient outcomes.

show abstract

Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival

Cited by 25 publications

References 30 publications

Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM)

Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM)

Adolescents and Young Adults (AYAs) With Initially Localized and Metastatic Bone Sarcomas: A Retrospective Single Center Analysis of Side Effect Management

Comparison of Hodgkin’s Lymphoma in Children and Adolescents. A Twenty Year Experience with MH’96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols

Contact Info

Product

Resources

About